Published On: Sun, Jun 15th, 2014

Teva wins US court ruling on generic breast cancer drug

Bristol-Myers Squibb’s Baraclude has $314 million in US annual sales.

Baraclude TEVA

 

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that the U.S. Court of Appeals for the Federal Circuit today upheld a ruling by the U.S. District Court for the District of Delaware finding Bristol-Myers Squibb’s entecavir compound claim of U.S. Patent No. 5, 206, 244 invalid. Teva’s ANDA for entecavir has received tentative approval from the U.S. Food and Drug Administration (FDA).

Teva will finalize the launch plans for this product once it receives final approval from the FDA.

Baraclude is marketed in the U.S. by Bristol-Myers Squibb and had annual sales of approximately $314 million in the United States, according to IMS data as of March 2014.

Read more about: , , , ,

Wordpress site Developed by Fixing WordPress Problems